What’s New in Antiretroviral Safety and Tolerability: Implications for Treatment

In this comprehensive online program led by expert faculty, review clinical strategies for applying the latest safety and tolerability data to minimize adverse events when selecting first-line ART and switching regimens in patients with HIV infection.
Kassem Bourgi, MD
Todd T. Brown, MD, PhD
Kristine Erlandson, MD
Rajesh T. Gandhi, MD
Daniel R. Kuritzkes, MD
Jordan E. Lake, MD, MSc
Brian Wood, MD

Video Module

In this interactive video module, expert faculty discuss safety and tolerability considerations for ART regimen selection and strategies to individualize regimen selection to reduce AEs associated with ART in persons with HIV

Kristine Erlandson, MD Rajesh T. Gandhi, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits Registered Nurses: 1.25 Nursing contact hours Pharmacists: 1.25 contact hours (0.125 CEUs) Released: April 24, 2020 Expired: April 23, 2021

Downloadable Slidesets

Review key data from AIDS 2020 and other sources informing individualized ART management to improve tolerability and minimize adverse events; topics include weight gain, cardiometabolic outcomes, and considerations for women of childbearing potential and during pregnancy.

Kassem Bourgi, MD Released: August 11, 2020

Review data and guideline recommendations informing ART management for specific patient populations to improve tolerability and minimize adverse events and potential drug-drug interactions

Kristine Erlandson, MD Rajesh T. Gandhi, MD Released: April 24, 2020

Review key data from 2020 conferences, including HIV Drug Therapy Glasgow and IDWeek, on potential causes and consequences of weight gain with ART and ART safety during conception or pregnancy.

Daniel R. Kuritzkes, MD Brian Wood, MD Released: November 9, 2020

ClinicalThought

During the past 2 years, guidelines have shifted their recommendations on use of DTG around the time of conception and during pregnancy. As data and guidance evolve, which ART regimens should we recommend to PWH in these settings?

Brian Wood, MD Released: April 20, 2020

Certain INSTIs and TAF are associated with excessive weight gain in PWH. Here’s my take on what we know, what we don’t, and the need for clinical trials to assess mechanism and management strategies.

Jordan E. Lake, MD, MSc Released: April 27, 2020

Here’s my take on what clinicians who treat HIV need to know about bone loss risk and bone health screening in our patients.

Todd T. Brown, MD, PhD Released: September 8, 2020

Data from 2020 conferences have shed new light on the issues of ARV-associated weight gain and ART safety during conception and pregnancy. Here are expert answers to your outstanding questions.

Daniel R. Kuritzkes, MD Brian Wood, MD Released: December 7, 2020

Clinical Focus

In this case-based, focused activity, review the latest data from 2020 scientific meetings on weight gain, cardiometabolic endpoints, and pregnancy outcomes with current ART regimens.

Kassem Bourgi, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: August 11, 2020 Expired: August 10, 2021

Podcast

Listen to Brian Wood, MD, discuss the latest HIV treatment safety and tolerability data from 2020 conferences, including weight gain with ART and ART safety in pregnancy.

Brian Wood, MD Released: November 23, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue